Chronic Spontaneous Urticaria Learning Zone
Transcript: Gülseren Tuncay on REMIX studies
Gülseren Tuncay, MD
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speakers and is not adjusted by Medthority.
The REMIX studies were undoubtedly very valuable as they demonstrated full disease control rates of up to 80% of patients in angioedema especially, not simply in this presentation, most of patients included in REMIX study had been suffering from CSU for more than one year. Therefore, all an impressive success rates of up to 80% was achieved.
It is still crucial to further investigate why the remaining 20% of patients did not reach well disease control. This suggests that we may be dealing with an heterogeneous group or a distinct phenotype. We learn from Michihiro's presentation on molecular differences between two phenotypes.
Whole exome sequencing and the proteomics were performed in a subset of CSU patients. However, since the study involved a family of African descent with certain comorbidities such as HIV, observed differences such as elevated CCL3 levels did not yield broadly meaningful and/or generalizable data beyond this specific context. Nevertheless, considering the favourable responses observed in angioedema patients with current treatments and ongoing phase studies, it can be said that existing therapies provide optimal responses across all CSU phenotypes.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
This content has been developed independently by Medthority who previously received educational funding from Novartis in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.